福莫特罗联合格隆溴铵治疗AECOPD对患者肺功能、血气指标及症状的影响

doi:10.20223/j.cnki.1000-8535.2024.10.015

摘要/Abstract

摘要： 目的探讨福莫特罗联合格隆溴铵对慢性阻塞性肺疾病急性加重期（AECOPD）患者的疗效。方法选择2021年1月—2023年6月廉江市人民医院收治的97例AECOPD患者进行研究,在双方知情基础上,通过单双号抽签方式分组,抽取单号纳入对照组（n=48,予以福莫特罗治疗）,抽取双号纳入观察组（n=48,予以福莫特罗联合格隆溴铵治疗）,对比两组肺功能指标、血气指标、症状改善情况及出现的不良反应。结果治疗后两组的肺功能指标均高于治疗前,而观察组各指标高于对照组（P<0.05）;治疗后两组PaO₂高于治疗前,PaCO₂低于治疗前,且观察组上述血气指标与对照组比较差异有统计学意义（P<0.05）;治疗后两组的CAT及SGRQ评分均低于治疗前,其中观察组评分低于对照组（P<0.05）;观察组（8.33%）与对照组（12.24%）不良反应率比较,差异不显著（P>0.05）。结论采用福莫特罗联合格隆溴铵治疗AECOPD患者,有助于改善患者肺功能,使其血气指标得到改善,还可有效缓解其呼吸道症状,且安全性得到保障。

关键词: 福莫特罗, 格隆溴铵, 慢性阻塞性肺疾病急性加重期

Abstract: Objective To explore the curative effect of formoterol combined with glycopyrronium bromide on patients with acute exacerbation of chronic obstructive pulmonary disease（AECOPD）. Methods The research cut-off period was from January 2021 to June 2023．A total of 97 patients with AECOPD were selected from Lianjiang People's Hospital for research．On the basis of mutual knowledge,they were divided into groups by odd and even numbers．The odd numbers were drawn into the control group（n=48,treated with formoterol）and the odd numbers were drawn into the observation group（n=48,treated with formoterol+glycopyrronium bromide）,the pulmonary function index,blood gas index,symptom improvement and adverse reactions were compared between the two groups. Results After treatment,the lung function indexes of the two groups were higher than those before treatment,while the indexes of the observation group were higher than those of the control group（P<0.05）．PaO₂ was higher and PaCO₂ was lower in the two groups after treatment,and the blood gas indexes in the observation group were different from those in the control group（P<0.05）．The scores of COPD assessment test and St. George's Respiratory Questionaire in the two groups after treatment were lower than those before treatment,while the scores in the observation group were lower than those in the control group（P<0.05）;There was no significant difference between the observation group（8.33%）and the control group（12.24%）（P>0.05）. Conclusions The choice of formoterol and qualified ammonium bromide for AECOPD is helpful to improve the lung function,blood gas index and respiratory symptoms,And the security is guaranteed．

Key words: formotero, glycopyrronium bromide, acute exacerbation of chronic obstructive pulmonary disease

李蕊, 王林文, 谢思丽, 陈晓坚. 福莫特罗联合格隆溴铵治疗AECOPD对患者肺功能、血气指标及症状的影响[J]. 广州医药, 2024, 55(10): 1188-1192.

LI Rui, WANG Linwen, XIE Sili, CHEN Xiaojian. Effects of formoterol and glycopyrronium bromide on lung function,blood gas indexes and symptoms of patients treated with AECOPD[J]. Guangzhou Medical Journal, 2024, 55(10): 1188-1192.

参考文献

[1] 王骥,程亚明,蔡荣.噻托溴铵联合布地奈德福莫特罗粉吸入剂对老年COPD患者PCT、CRP、通气功能、凝血指标的影响[J].中国老年学杂志,2022,42(14):3448-3451.
[2] 孙田霞. 噻托溴铵粉雾剂联合布地奈德福莫特罗粉吸入剂对COPD稳定期患者的疗效[J].河南医学研究,2020,29(15):2806-2807.
[3] 李艳萍,殷俊,杨旖,等.布地奈德福莫特罗吸入治疗对COPD急性期及稳定期患者肺功能气道阻力的影响[J].广东医学,2020,41(22):2307-2311.
[4] 杨晓丽,蒋萍,王栋宇.三种方案治疗C、D级慢性阻塞性肺疾病稳定期患者的有效性及安全性对比研究[J].实用心脑肺血管病杂志,2020,28(9):100-104.
[5] 中华医学会呼吸病学分会慢性阻塞性肺疾病学组,中国医师协会呼吸医师分会慢性阻塞性肺疾病工作委员会.慢性阻塞性肺疾病诊治指南(2021年修订版)[J].中华结核和呼吸杂志,2021,44(3):170-205.
[6] 唐彩平,靳青,王惠琴.噻托溴铵联合布地奈德福莫特罗治疗慢性阻塞性肺疾病的效果及对血气分析指标、miR-145、miR-146a的影响[J].临床医学研究与实践,2023,8(27):21-24.
[7] 梁超,简阅,肖伟,等.噻托溴铵联合布地奈德福莫特罗治疗COPD的临床疗效及对COX-2、PLA2、MMP-9水平的影响[J].医学综述,2022,28(21):4348-4353.
[8] 何昭锜,幸金鑫.噻托溴铵联合布地奈德福莫特罗治疗COPD的临床效果分析[J].现代诊断与治疗,2022,33(10):1460-1463.
[9] 崔可慧,林震宇,谷秀.布地奈德福莫特罗粉吸入剂联合噻托溴铵粉吸入剂在老年急性加重期慢性阻塞性肺疾病患者中的应用效果观察[J].中国医药,2022,17(9):1343-1347.
[10] 师伟,赵琰,张娜,等.布地奈德福莫特罗粉联合噻托溴铵粉治疗慢阻肺患者的临床效果分析[J].现代诊断与治疗,2022,33(23):3510-3512.
[11] 黄万立,薛凌,毛方术,等.噻托溴铵粉吸入剂联合布地奈德福莫特罗粉吸入剂对重症COPD稳定期患者肺功能的影响研究[J].临床研究,2019,27(8):98-99.
[12] 夏婉飞,黄国华,古辉,等.噻托溴铵/奥达特罗治疗C、D组慢性阻塞性肺疾病稳定期患者的效果[J].广州医药,2023,54(4):100-103,114.
[13] 宋卫珍,董凌云.噻托溴铵吸入剂联合布地奈德福莫特罗治疗对老年急性加重期COPD患者肺功能及对HMGB1、Copeptin的影响[J].中国老年学杂志,2020,40(9):1847-1851.
[14] 宋丽英. 福莫特罗联合格隆溴铵对COPD急性加重高风险患者肺功能、炎症指标的影响[J].中国临床药学杂志,2022,31(9):670-675.
[15] 宿光明. 布地奈德福莫特罗吸入粉雾剂(Ⅱ)联合噻托溴铵对COPD合并支气管哮喘患者的治疗效果[J].河南医学研究,2021,30(8):1470-1472.
[16] 李峰. 布地奈德福莫特罗粉吸入剂联合噻托溴铵治疗AECOPD的效果观察[J].现代诊断与治疗,2021,32(9):1379-1381.
[17] 张冈毅,莫鉴锋,李绍清,等.布地奈德福莫特罗吸入剂联合氨溴索治疗COPD急性加重期的临床疗效[J].岭南急诊医学杂志,2023,28(2):124-125,133.
[18] 张若丹,柯英,曹美,等.孟鲁司特钠联合布地奈德福莫特罗对COPD患者肺功能及炎症介质、BNP、ApoA1的影响[J].中南医学科学杂志,2023,51(4):554-557.
[19] 张娟娟,张莹,王惠欣.气道正压通气联合布地奈德福莫特罗吸入粉雾剂对COPD合并OSA患者临床疗效观察[J].中华保健医学杂志,2023,25(3):344-346.
[20] 杨艳薇. 乙酰半胱氨酸联合布地奈德福莫特罗治疗COPD稳定期患者的疗效分析[J].中国现代药物应用,2023,17(3):108-110.
[21] 樊国丽,彭毅,甄世林,等.布地格福吸入气雾剂治疗哮喘-慢阻肺重叠综合征临床效果分析[J].中国现代医药杂志,2021,23(8):80-81.
[22] 范波,南武娟,王惠琴.噻托溴铵联合布地奈德福莫特罗对哮喘-慢阻肺重叠综合征患者炎症因子、气道重塑因子及肺功能的影响[J].临床医学研究与实践,2023,8(23):25-28.
[23] 马俊彦,魏永梅,王登本,等.茚达特罗/格隆溴铵和长效β2受体激动剂/长效M受体阻滞剂治疗慢性阻塞性肺疾病稳定期有效性及不良反应发生Meta分析[J].陕西医学杂志,2021,50(10):1309-1313,封3.
[24] 喻冬芹. 格隆溴铵联合孟鲁司特钠治疗中重度慢阻肺稳定期患者的疗效评价[J].中国实用乡村医生杂志,2023,30(2):46-49,53.